Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05222386 · ClinicalTrials.gov registry record · NA

Community Outreach for Palliative Engagement -- Parkinson Disease

A NA study of Parkinson Disease and Multiple System Atrophy, sponsored by University of Rochester.

Active
Registry status
NA
Development phase
632
Enrollment target
1
Study location

NCT05222386: Active NA study of Parkinson Disease and Multiple System Atrophy, sponsored by University of Rochester.

NCT05222386 is a NA study of Parkinson Disease and Multiple System Atrophy that is active but no longer recruiting, run by University of Rochester. The registered enrollment target is 632 participants, below the 5,324-participant average among 297 other Parkinson Disease trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05222386, a NA study of Parkinson Disease and Multiple System Atrophy, is active but no longer recruiting, sponsored by University of Rochester.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
632 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body Dementia (LBD) or related conditions and their care partners. Palliative care is a treatment approach focused on improving quality of life by relieving suffering in the areas of physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Telemedicine is the use of technology that allows participants to interact with a health care provider without being physically near the provider.

Primary Outcome

Primary Outcome: Patient (Quality of Life): Investigators will use the Quality of Life: Alzheimer's Disease (QOL-AD) to understand the specific challenges and support preferences of persons living with PD, their family care partner, and healthcare professionals, through the Quality of Life: Alzheimer's Disease (QOL-AD). Range 13-52, higher scores = better QOL

Interventions

  • OTHER Parkinson Disease Standard Care
  • OTHER Online Community-Supported Palliative Care

Study Locations (1)

New York

  • University of Rochester Medical Center for Health + Technology - Rochester

Trial Details

FieldValue
Enrollment Target 632 participants
Start Date 2022-04-26
Est. Completion 2026-12-31
Phase NA
University of Rochester

636 total trials

What the registry record for NCT05222386 still lists

NCT05222386 is an interventional study that assigns participants to a tested intervention. The registered 632 participants enrollment target is mid-sized for trials with a published cap, below the 5,324-participant average among 297 other Parkinson Disease trials with a reported enrollment target (88% lower).

The record links to 9 conditions, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Parkinson Disease Standard Care is the first listed.

NCT05222386 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05222386 about?

NCT05222386 is a clinical study titled "Community Outreach for Palliative Engagement -- Parkinson Disease". The purpose of this study is to learn more about the effectiveness of palliative care training for community physicians and telemedicine support services for patients and carepartners with Parkinson's disease and Lewy Body Dementia (LBD) or related conditions and their care partners. Palliative care...

What is the current status of trial NCT05222386?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 632 participants. The study started on 2022-04-26. Estimated completion is 2026-12-31.

What conditions does trial NCT05222386 study?

This clinical trial studies the following conditions: Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Progressive Supranuclear Palsy, Corticobasal Degeneration.

What interventions are being tested in trial NCT05222386?

The interventions under investigation include: Parkinson Disease Standard Care (OTHER), Online Community-Supported Palliative Care (OTHER).

Who is sponsoring clinical trial NCT05222386?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05222386 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05222386's enrollment target sits among peer trials

632 19th of 297 higher than 279 of 297 other Parkinson Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05744973 · 631 participants

    Multi-level Predictors of Structural Racism and Discrimination and Associations With Health and Well-being Across the Life Course in Diverse Families

  • NCT00573027 · 634 participants · NA

    Heart Disease of the Small Arteries in Women and Men

  • NCT04108156 · 634 participants · Phase 3

    A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME

  • NCT07237295 · 634 participants · NA

    CommunityRx-Kidney Health

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05222386, the US trial registry maintained by the National Library of Medicine. NCT05222386 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.